|Videos|January 14, 2016

Dr. Alexander Kutikov on Options Afforded to Kidney Cancer Patients

Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.

Alexander Kutikov, MD, FACS, associate professor of Urologic Oncology, Fox Chase Cancer Center, discusses the options patients with a renal tumor have. Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.

Stay up to date on practice-changing data in community practice.

Dr. Alexander Kutikov on Options Afforded to Kidney Cancer Patients

Related Content

Staying Aware of Psychosocial and Systemic Barriers to Allogeneic SCT

Behind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer

Alcohol and Breast Cancer: Closing a Dangerous Awareness Gap in Young Women

Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT

Improving Referral Pathways for High-Risk Patients

Latest CME

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Empire State Hematology & Oncology Society (New York)

South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

24th Annual International Congress on the Future of Breast Cancer® East

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Colorado Oncology Society

Satellite Symposia at the Annual Radiation Oncology Meeting

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma

Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT

FDA Grants Priority Review to Subcutaneous Amivantamab for Advanced HNSCC

NCCN Lists Gedatolisib Regimens as Preferred Option in HR+/HER2– Metastatic Breast Cancer

FDA Grants Fast Track and RMAT Designations to Cema-Cel in LBCL